fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2010-02-19
Biotech partner: Vivalis (France)
Pharma Partner: Kyoto Biken (Japan)
Type of agreement: * licensing
Compound: EB66® cell line for the production of viral vaccines
Nature of the agreement: Vivalis has granted Kyoto Biken rights to its duck embryonic stem cell derived EB66®
cell line to evaluate EB66® cell line for the production of veterinary viral vaccines.
Financial terms of the agreement: Financial details were not disclosed.


Go back to previous page